Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C99761
http://purl.obolibrary.org/obo/NCIT_C99761
|
|---|---|
| Preferred Name | Antiangiogenic Drug Combination TL-118 |
| Definitions |
A proprietary, oral suspension containing a combination of agents comprised of a nonsteroidal anti-inflammatory agent, an alkylating agent, a histamine H2 antagonist and a sulfonamide with potential anti-angiogenic and antineoplastic activities. Antiangiogenic drug combination TL-118 is administrated as a specific dosing regimen and may result in a synergistic effect and reduce angiogenesis and inhibit tumor cell proliferation.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A proprietary, oral suspension containing a combination of agents comprised of a nonsteroidal anti-inflammatory agent, an alkylating agent, a histamine H2 antagonist and a sulfonamide with potential anti-angiogenic and antineoplastic activities. Antiangiogenic drug combination TL-118 is administrated as a specific dosing regimen and may result in a synergistic effect and reduce angiogenesis and inhibit tumor cell proliferation. |
|---|---|
| prefLabel | Antiangiogenic Drug Combination TL-118
|
| label | Antiangiogenic Drug Combination TL-118
|
| PDQ_Closed_Trial_Search_ID | 723650
|
| code | C99761
|
| prefixIRI | NCIT:C99761
|
| in_subset | |
| Preferred_Name | Antiangiogenic Drug Combination TL-118
|
| Maps_To | Antiangiogenic Drug Combination TL-118
|
| NCI_Drug_Dictionary_ID | 723650
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 723650
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C3274907
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |